Canada · Delayed Price · Currency is CAD Revance Therapeutics Statistics
Total Valuation
TSXV:FAS has a market cap or net worth of CAD 8.15 million. The enterprise value is 7.63 million.
| Market Cap | 8.15M |
| Enterprise Value | 7.63M |
Important Dates
The last earnings date was Tuesday, July 29, 2025.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TSXV:FAS has 67.96 million shares outstanding. The number of shares has increased by 249.04% in one year.
| Current Share Class | 67.96M |
| Shares Outstanding | 67.96M |
| Shares Change (YoY) | +249.04% |
| Shares Change (QoQ) | +62.72% |
| Owned by Insiders (%) | 6.70% |
| Owned by Institutions (%) | n/a |
| Float | 63.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.20 |
| P/TBV Ratio | 2.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -16.31 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -8.06 |
Financial Position
The company has a current ratio of 1.05
| Current Ratio | 1.05 |
| Quick Ratio | 0.81 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -14.11% and return on invested capital (ROIC) is -7.84%.
| Return on Equity (ROE) | -14.11% |
| Return on Assets (ROA) | -6.74% |
| Return on Invested Capital (ROIC) | -7.84% |
| Return on Capital Employed (ROCE) | -11.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +17.39% in the last 52 weeks. The beta is 1.90, so TSXV:FAS's price volatility has been higher than the market average.
| Beta (5Y) | 1.90 |
| 52-Week Price Change | +17.39% |
| 50-Day Moving Average | 0.10 |
| 200-Day Moving Average | 0.08 |
| Relative Strength Index (RSI) | 48.93 |
| Average Volume (20 Days) | 658,634 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -415,449 |
| Pretax Income | -467,633 |
| Net Income | -467,633 |
| EBITDA | n/a |
| EBIT | -415,449 |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
The company has 528,239 in cash and n/a in debt, giving a net cash position of 528,239 or 0.01 per share.
| Cash & Cash Equivalents | 528,239 |
| Total Debt | n/a |
| Net Cash | 528,239 |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 3.70M |
| Book Value Per Share | 0.07 |
| Working Capital | 34,804 |
Cash Flow
In the last 12 months, operating cash flow was -392,589 and capital expenditures -554,010, giving a free cash flow of -946,599.
| Operating Cash Flow | -392,589 |
| Capital Expenditures | -554,010 |
| Free Cash Flow | -946,599 |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSXV:FAS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -249.04% |
| Shareholder Yield | n/a |
| Earnings Yield | -5.73% |
| FCF Yield | -11.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 20, 2023. It was a reverse split with a ratio of 0.1.
| Last Split Date | Dec 20, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |